You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Latest Advances With Targeted Therapies for Advanced/Metastatic Urothelial Carcinoma: Evidence and Implications

  • Authors: Thomas Powles, MBBS, MRCP, MD; Yohann Loriot, MD, PhD; Jonathan Rosenberg, MD
  • CPD Released: 12/10/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 12/10/2022
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematology and oncology specialists, urologists and pathologists.

The goal of this activity is to increase physician knowledge of the rationale and available evidence for emerging targeted therapies as well as their implications for the management of patients with advanced/metastatic urothelial carcinoma.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Rationale for emerging targeted therapies for advanced/metastatic urothelial carcinoma
    • Available evidence for emerging targeted therapies for advanced/metastatic urothelial carcinoma
  • Demonstrate greater confidence in their ability to
    • Understand the clinical implications of the available evidence for emerging targeted therapies for the treatment of advanced/metastatic urothelial carcinoma


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

All of the relevant financial relationships listed for these individuals have been mitigated.


Faculty

  • Thomas Powles, MBBS, MRCP, MD

    Professor of Genitourinary Oncology
    Barts Cancer Institute
    Queen Mary University of London
    London, United Kingdom

    Disclosures

    Disclosure: Thomas Powles, MBBS, MRCP, MD, has the following relevant financial relationships:
    Advisor or consultant for: Astellas; AstraZeneca; Bristol Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; Merck Sharpe & Dohme; Novartis; Pfizer; Roche; Seattle Genetics
    Grants for clinical research from: Astellas; AstraZeneca; Bristol Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck; Merck Serono; Merck Sharpe & Dohme; Novartis; Pfizer; Roche; Seagen, Inc
    Other: Travel: AstraZeneca; Ipsen; Merck Sharpe & Dohme; Pfizer; Roche

  • Yohann Loriot, MD, PhD

    Department of Cancer Medicine
    Université Paris-Saclay
    Institut Gustave Roussy
    Villejuif, France

    Disclosures

    Disclosure: Yohann Loriot, MD, PhD has the following relevant financial relationships:
    Advisor or consultant for: Astellas; AstraZeneca; Bristol Myers Squibb; Immunomedics; Janssen; Merck Kg; Merck Sharpe & Dohme; Pfizer; Roche; Seagen, Inc
    Grants for clinical research from: Celsius; Janssen; Merck Sharpe & Dohme; Sanofi

  • Jonathan Rosenberg, MD

    Medical Oncologist
    Chief, Genitourinary Medical Oncology Service
    Division of Solid Tumor Oncology
    Enno W. Ercklentz Chair
    Memorial Sloan Kettering Cancer Center
    New York, New York, United States

    Disclosures

    Disclosure: Jonathan Rosenberg, MD, has the following relevant financial relationships:
    Advisor or consultant for: Astellas; BioClin; Boehringer Ingelheim; Bristol Myers Squibb; EMD Serono; Immunomedicas/Gilead; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; Pfizer; QED; Roche/Genentech; Seagen, Inc; Tyra Biosciences
    Speaker or a member of a speakers bureau for: EMD Serono
    Grants for clinical research from: Astellas; QED; Roche/Genentech; Seattle Genetics

Editors

  • Megan Cannon, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Megan Cannon, PhD, has disclosed no relevant financial relationships.

  • Ryan Blanchard, BS

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Disclosure: Ryan Blanchard, BS, has disclosed no relevant financial relationships.

Content Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.5 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Latest Advances With Targeted Therapies for Advanced/Metastatic Urothelial Carcinoma: Evidence and Implications

Authors: Thomas Powles, MBBS, MRCP, MD; Yohann Loriot, MD, PhD; Jonathan Rosenberg, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 12/10/2021

Valid for credit through: 12/10/2022

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

Current Challenges for Managing Advanced/Metastatic Urothelial Carcinoma: Where Are We Now?

Dr Powles reviews the current landscape for locally advanced/metastatic urothelial carcinoma and unmet needs.
Thomas Powles, MBBS, MRCP, MD

The Role of ADCs for Advanced/Metastatic Urothelial Carcinoma

In this video, Dr Powles provides the rationale for antibody-drug conjugates and the supporting evidence from key clinical trials.
Thomas Powles, MBBS, MRCP, MD

The Role of FGFR Inhibitors for Advanced/Metastatic Urothelial Carcinoma

Join Dr Loriot for a deep dive into FGFR alterations and an overview of the recent evidence behind the use of FGFR inhibitors.
Yohann Loriot, MD, PhD

Combining Targeted Therapies With Immunotherapies: Where Now, Where Tomorrow?

Listen to Dr Rosenberg discuss the strategies driving combination approaches with targeted agents and immunotherapy.
Jonathan Rosenberg, MD

Summary and Key Takeaways

Dr Powles provides a brief overview of the key messages from this program.
Thomas Powles, MBBS, MRCP, MD
 

Educational Impact Challenge

The goal of this activity is to increase physician knowledge of the rationale and available evidence for emerging targeted therapies as well as their implications for the management of patients with advanced/metastatic urothelial carcinoma.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print